Faeth Therapeutics (Faeth), a clinical-stage biotechnology company, announced that Oliver Maddocks, Co-Founder and Chief Scientific Officer, and Debbie Chirnomas, M.D., Chief Medical Officer, will present today at the Raymond James Biotech Private Company Showcase. Oliver and Debbie will discuss Faeth’s lead PIKTOR program development plans and participate in a Q&A following the presentation.

Faeth's lead program, FTH-001/003 or "PIKTOR," features the combination of serabelisib, a PI3Kɑ inhibitor, and sapanisertib, an mTORC 1/2 inhibitor. This combination effectively targets and shuts down the PI3K pathway, one of the most frequently mutated pathways in cancer. PIKTOR has demonstrated impressive outcomes in a Phase 1b trial across endometrial, ovarian, and breast cancers in conjunction with paclitaxel. Additionally, Faeth's second clinical initiative involves FTH-002, a specially designed amino acid sachet administered alongside an amino acid-restricted diet and radio/chemotherapy.

Faeth boasts a strong clinical and preclinical pipeline, fueled by its MetabOS discovery platform. This platform utilizes AI, machine learning, and carefully selected data sets to pinpoint targets tailored to specific tumor genotypes.

Established by luminary oncology researchers including Drs. Lew Cantley, Siddhartha Mukherjee, and Karen Vousden, Faeth is dedicated to developing therapies that target cancer metabolism. While the significance of metabolism in cancer growth is recognized, it is still largely underutilized in treatment, with only a handful of therapies available. Faeth employs a unique strategy that combines an in-depth understanding of cancer metabolism, functional genomics, and computational biology to create effective, less toxic treatments.

About Faeth Therapeutics

Faeth Therapeutics is a clinical-stage biotechnology company at the forefront of oncology research with a robust clinical and preclinical pipeline powered by its AI-driven MetabOS discovery platform. Faeth’s lead program, PIKTOR, has shown outstanding clinical results in a Phase 1b trial and is advancing into a Phase 2 trial in endometrial cancer in 2024. For additional information, visit www.faeththerapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240717288408/en/